title: Multidisciplinary approach to Wilms' tumor: 18 years of experience.
abstract: BACKGROUND
  The aim was to evaluate the characteristics of Wilms' tumor and the results of combined modality treatment obtained in our center in Turkey.
  
  
  METHODS
  From January 1978 to December 1996, 106 patients with Wilms' tumor were diagnosed. Of these 106 patients, 61 were male and 45 were female (M/F = 1,35); the median age at diagnosis was 39 months. The distribution of the 106 patients according to clinical stage was stage I 10%, stage II 42%, stage III 35%, stage IV 9% and stage V 4%. Histologically, 102 of the cases could be evaluated: favorable histology was diagnosed in 88.2% and unfavorable histology in 11.8% of the patients. Ninety-eight patients were treated according to NWTS and eight patients according to SIOP protocols.
  
  
  RESULTS
  The EFS and overall survival rates at 2 years were 74.2 and 79.5% respectively, and at 5 years 72.4 and 76.6% respectively.
  
  
  CONCLUSIONS
  As a developing country we evaluated our survival rates and report an improvement in treatment in recent years.
authors.affiliation: Cerrahpaşa Medical Faculty, Department of Paediatric Haematology-Oncology, University of Istanbul, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Yildiz
authors.forename: L
authors.initials: L
authors.lastname: Yüksel
authors.forename: A
authors.initials: A
authors.lastname: Ozkan
authors.forename: H
authors.initials: H
authors.lastname: Apak
authors.forename: T
authors.initials: T
authors.lastname: Celkan
authors.forename: N
authors.initials: N
authors.lastname: Danismend
authors.forename: C
authors.initials: C
authors.lastname: Büyükünal
authors.forename: Y
authors.initials: Y
authors.lastname: Söylet
authors.forename: N
authors.initials: N
authors.lastname: Sarimurat
authors.forename: S
authors.initials: S
authors.lastname: Dervisoglu
authors.forename: F
authors.initials: F
authors.lastname: Aksoy
authors.forename: G
authors.initials: G
authors.lastname: Atkovar
authors.forename: S
authors.initials: S
authors.lastname: Okkan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D009392:Nephrectomy; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D014421:Turkey; D009396:Wilms Tumor / Q000473:pathology / Q000556:secondary / Q000628:therapy*